Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Sign Up to like & getrecommendations! Published in 2022 at "mBio"
DOI: 10.1128/mbio.01699-22
Abstract: The clinical benefit of CAS+IMD in hospitalized seronegative patients with COVID-19 has previously been demonstrated, although these studies observed no clinical benefit in seropositive patients. As the prevalence of SARS-CoV-2-seropositive individuals rises due to both… read more here.
Keywords: borderline neutralizing; cas imd; sars cov; neutralizing antibodies ... See more keywords